# Study to Assess Efficacy of AZD1236 in Patients With Cystic Fibrosis

> **NCT00812045** · PHASE2 · WITHDRAWN · sponsor: **AstraZeneca** · enrollment: 44 (estimated)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** AZD1236
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00812045
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-12
- **Primary completion:** —
- **Final completion:** 2010-08
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2009-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00812045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00812045, "Study to Assess Efficacy of AZD1236 in Patients With Cystic Fibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00812045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*